NEW YORK, March 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018.
The report profiles 127 companies including many key and niche players such as AbbVie Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Aspen Pharmacare Holdings Limited, AstraZeneca Plc, BEACON Pharmaceutical Limited, BIAL Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Elan Corporation Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fabre-Kramer Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A, Shire Plc, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group.Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3CNS Disorders I-3Anti-Alzheimer's Drugs I-3Anti-Parkinson's Drugs I-4Anti-Epilepsy Drugs I-4Pain Management Drugs I-4Anti-Psychotics Drugs I-5Bipolar disorder I-5Schizophrenia I-5Anti-Depressants Drugs I-5Others I-6Attention Deficit Hyperactivity Disorder I-6Multiple Sclerosis I-6Insomnia I-6Restless Legs Syndrome I-7Anxiety I-7